U.S., July 26 -- ClinicalTrials.gov registry received information related to the study (NCT07085611) titled 'Neutralizing Power of Serum Antibodies - 2' on July 17.
Brief Summary: Severe forms of COVID-19 and Monkeypox affect immunocompromised and comorbid individuals. Vaccination and monoclonal antibody therapies induce neutralizing antibodies. This neutralizing power is recognized as a correlate of protection against a new infection. This study aims to describe the neutralizing power of serum and nasal antibodies over time, in relation to SARS-CoV-2 and MPXV vaccines or treatments received.
Study Start Date: July 31
Study Type: INTERVENTIONAL
Condition:
COVID-19
SARS-CoV-2 Viraemia
Monkey Pox
Vaccination
Serum
Mucosal Immunity
Inter...